Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 4/2011

01.08.2011 | Review Article

Drug-Induced Acneiform Eruption

verfasst von: Aurélie Du-Thanh, Nicolas Kluger, Houdna Bensalleh, Prof. Bernard Guillot

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Drug-induced acne is a specific subset of acne that usually has some specific features, namely a monomorphic pattern, an unusual location of the lesions beyond the seborrheic areas, an unusual age of onset, a resistance to conventional acne therapy and, of course, the notion of a recent drug introduction. Many drugs can be responsible for such a clinical pattern. Corticosteroids, neuropsychotherapeutic drugs, antituberculosis drugs, and immunomodulating molecules are the more classical drugs associated with induced acne. Recently, new drugs, mainly targeted therapy in the field of oncology, such as epidermal growth factor receptor inhibitors, have been associated with an increased frequency of this adverse effect. Disruption of the culprit drug is rarely mandatory in cases of drug-induced acne. Close cooperation between the dermatologist and medical staff in charge of the patient is an important challenge to achieve optimal management of the initial disease.
Literatur
1.
2.
Kligman AM, Plewig G. Classification of acne. Cutis 1976; 17: 520–2PubMed
3.
Brunner MS, Riddell Jr JM, Best WR. Cutaneous side effects of ACTH, cortisone, and pregnenolone therapy. J Invest Dermatol 1951; 16: 205–9PubMed
4.
Sullivan M, Zeligman I. Acneform eruption due to corticotropin. AMA Arch Dermatol 1956; 73: 133–41CrossRef
5.
Plewig G, Kligman AM. Induction of acne by topical steroids. Arch Dermatol Forsch 1973; 247: 29–52PubMed
6.
Fung MA, Berger TG. A prospective study of acute-onset steroid acne associated with administration of intravenous corticosteroids. Dermatology 2000; 200: 43–4CrossRef
7.
Monk B, Cunlife WJ, Layton AM, et al. Acne induced by inhaled corticosteroids. Clin Exp Derm 1993; 1: 148–50CrossRef
8.
Guillot B. Adverse skin reactions to inhaled corticosteroids. Expert Opin Drug Saf 2002; 1: 325–9PubMedCrossRef
9.
Bedane C, Souyri N. Induced acne. Ann Dermatol Venereol 1990; 117: 53–8PubMed
10.
11.
Fyrand O, Fiskaadal HJ, Trygstad O. Acne in pubertal boys undergoing treatment with androgens. Acta Derm Venereol 1992; 72: 148–9PubMed
12.
Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch Dermatol 1989; 125: 571–2PubMedCrossRef
13.
Melnik B, Jansen T, Grabbe S. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges 2007; 5: 110–7PubMedCrossRef
14.
Gerber PA, Kukova G, Meller S, et al. The dire consequences of doping. Lancet 2008; 372: 1544CrossRef
15.
Yildizbas B, Sahin HG, Kolusari A, et al. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. Eur J Contracept Reprod Health Care 2007; 12: 248–52PubMedCrossRef
16.
Funk S, Miller MM, Mishell Jr DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319–26PubMedCrossRef
17.
Gezginc K, Balci O, Karatayli R, et al. Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care 2007; 12: 362–5PubMedCrossRef
18.
Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009; 91: 1646–53PubMedCrossRef
19.
Cohen EB, Rossen NN. Acne vulgaris in connection with the use of progestagens in a hormonal IUD or a subcutaneous implant [in Dutch]. Ned Tijdschr Geneeskd 2003; 147: 2137–9PubMed
20.
Ilse JR, Greenberg HL, Bennett DD. Levonorgestrel-releasing intrauterine system and new-onset acne [letter]. Cutis 2008; 82: 158PubMed
21.
Greenberg RD. Acne vulgaris associated with antigonadotropic (Danazol) therapy. Cutis 1979; 24: 431–3PubMed
22.
Thioly-Bensoussan D, Charpentier A, Triller R, et al. Iatrogenic acne caused by amineptin (Survector): apropos of 8 cases. Ann Dermatol Venereol 1988; 115: 1177–80PubMed
23.
Grupper C. New iatrogenic acne: acne caused by amineptin (Survector). Ann Dermatol Venereol 1988; 115: 1174–6PubMed
24.
Vexiau P, Gourmel B, Husson C, et al. Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases. Ann Dermatol Venereol 1988; 115: 1180–2PubMed
25.
Teillac D, Weber MJ, Lowenstein W, et al. Acne caused by Survector [in French]. Ann Dermatol Venereol 1988; 115: 1183–4PubMed
26.
Lévigne V, Faisant M, Mourier CG, et al. Monstrous acne in the adult: inducer role of Survector? Ann Dermatol Venereol 1988; 115: 1184–5PubMed
27.
Vexiau P, Gourmel B, Julien R, et al. Severe acne-like lesions caused by amineptine overdose [letter]. Lancet 1988; 1: 585PubMedCrossRef
28.
Vexiau P, Gourmel B, Castot A, et al. Severe acne due to chronic amineptine overdose. Arch Dermatol Res 1990; 282: 103–7PubMedCrossRef
29.
Huet P, Dandurand M, Joujoux JM, et al. Acne induced by amineptin: adnexal toxiderma. Ann Dermatol Venereol 1996; 123: 817–20PubMed
30.
Duriot JF, Dutertre JP, Grenier JM, et al. Amineptin dependence and iatrogenic acne: review of the literature apropos of a case. Ann Med Psychol (Paris) 1991; 149: 795–7
31.
Farella V, Sberna F, Knöpfel B, et al. Acne-like eruption caused by amineptine. Int J Dermatol 1996; 35: 892–3PubMedCrossRef
32.
Bettoli V, Trimurti S, Lombardi AR, et al. Acne due to amineptine abuse. J Eur Acad Dermatol Venereol 1998; 10: 281–3PubMedCrossRef
33.
Grimalt R, Mascaró-Galy JM, Ferrando J, et al. Guess what? Macronodular iatrogenic acne due to amineptine. Eur J Dermatol 1999; 9: 491–2PubMed
34.
De Gálvez Aranda MV, Sánchez PS, Alonso Corral MJ, et al. Acneiform eruption caused by amineptine: a case report and review of the literature. J Eur Acad Dermatol Venereol 2001; 15: 337–9PubMed
35.
Ponte CD. Maprotiline induced acne. Am J Psychiatry 1982; 139: 141PubMed
36.
Ossofsky J. Amenorrhea in endogenous depression. Int Pharmacopsychiatry 1974; 9: 100–8PubMed
37.
Kusumi Y. A cutaneous side effect of lithium: report of two cases. Dis Nerv Syst 1971; 32: 853–4PubMed
38.
Ruíz-Maldonado R, Pérez de Francisco C, Tamayo L. Lithium dermatitis [letter]. JAMA 1973; 224: 1534PubMedCrossRef
39.
Yoder FW. Acneiform eruption due to lithium carbonate [letter]. Arch Dermatol 1975; 111: 396–7PubMedCrossRef
40.
Sarantidis D, Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry 1983; 143: 42–50PubMedCrossRef
41.
Yeung CK, Chan HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3–8PubMedCrossRef
42.
Heng MC. Lithium carbonate toxicity: acneiform eruption and other manifestations. Arch Dermatol 1982; 118: 246–8PubMedCrossRef
43.
Jenkins RB, Ratner AC. Diphenyl hydantoin and acne [letter]. N Engl J Med 1972; 287: 148PubMed
44.
Frentz G. Acne and phenytoin [in Danish]. Ugeskr Laeger 1977; 139: 338–9
45.
Norris JF, Cunliffe WJ. Phenytoin-induced gum hypertrophy improved by isotretinoin. Int J Dermatol 1987; 26: 602–3PubMedCrossRef
46.
Gunwald MH, Ben-Dor D, Livni E, et al. Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int J Dermatol 1990; 29: 559–61CrossRef
47.
Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine. J Clin Psychiatry 2004; 65: 1720–2PubMedCrossRef
48.
Hesse S, Berbis P, Lafforgue P, et al. Acne and enthesiopathy during antiepileptic treatment. Ann Dermatol Venereol 1992; 119: 655–8PubMed
49.
Greenwood R, Fenwick PB, Cunliffe WJ. Acne and anti-convulsants. Br Med J 1983; 287: 1669–70CrossRef
50.
Mishra B, Praharaj SK, Prakash R, et al. Aripiprazole-induced acneiform eruption. Gen Hosp Psychiatry 2008; 30: 479–81PubMedCrossRef
51.
Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002; 3: 329–39PubMedCrossRef
52.
Ade G. Poussées d’eczéma séborrhéique ou acné iforme probablement consécutives áun traitement ála vitamine B12 [letter]. Dermatologica 1958; 116: 366CrossRef
53.
Dugois P, Amblard P, Imbert R, et al. Acne due to vitamin B12 [in French]. Bull Soc Fr Dermatol Syphiligr 1969; 76: 382–3PubMed
54.
Puissant A, Vanbremeersch F, Monfort J, et al. A new iatrogenic dermatosis: acne caused by vitamin B12 [in French]. Bull Soc Fr Dermatol Syphiligr 1967; 74: 813–5PubMed
55.
Dupré A, Albarel N, Bonafe JL, et al. Vitamin B-12 induced acnes. Cutis 1979; 24: 210–1PubMed
56.
Sheretz EF. Acneiform eruption due to ‘megadose’ vitamins B6 and B12. Cutis 1991; 48: 119–20
57.
Braun-Falco O, Lincke H. The problem of vitamin B6/B12 acne: a contribution on acne medicamentosa. MMW Munch Med Wochen Schr 1976; 118: 155–60
58.
Blatt J, Lee PA. Severe acne and hyperandrogenemia following dactinomycin. Med Pediatr Oncol 1993; 5: 373–4CrossRef
59.
Schmoeckel C, von Liebe V. Acneiformexanthema caused by azathioprine [in German]. Hautarzt 1983; 34: 413–5PubMed
60.
Bencini PL, Montagnino G, Crosti C, et al. Cutaneous lesion in 67 cyclosporin-treated renal transplant recipients. Dermatologica 1986; 172: 24–30PubMedCrossRef
61.
Strahan JE, Burch JM. Cyclosporine-induced infantile nodulocystic acne. Arch Dermatol 2009; 145: 797–9PubMedCrossRef
62.
Richter A, Beideck S, Bender W, et al. Epidermal cysts and folliculitis caused by cyclosporin A [in German]. Hautarzt 1993; 44: 521–3PubMed
63.
el-Shahawy MA, Gadallah MF, Massry SG. Acne: a potential side effect of cyclosporine A therapy. Nephron 1996; 72: 679–82PubMedCrossRef
64.
Carnero L, Silvestre JF, Guijarro J, et al. Nuchal acne keloidalis associated with cyclosporin. Br J Dermatol 2001; 144: 429–30PubMedCrossRef
65.
Bunker CB, Rustin MH, Dowd PM. Isotretinoin treatment of severe acne in posttransplant patients taking cyclosporine. J Am Acad Dermatol 1990; 22: 693–4PubMedCrossRef
66.
Abel EA. Isotretinoin treatment of severe cystic acne in a heart transplant patient receiving cyclosporine: consideration of drug interactions [letter]. J Am Acad Dermatol 1991; 24: 511PubMedCrossRef
67.
Hazen PE, Walker AE, Stewart JJ, et al. Successful use of isotretinoin in a patient on cyclosporine: apparent lack of toxicity [letter]. Int J Dermatol 1993; 32: 466PubMedCrossRef
68.
Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006; 55: 139–42PubMedCrossRef
69.
Mahé E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476–82PubMedCrossRef
70.
Lübbe J, Sorg O, Malé PJ, et al. Sirolimus-induced inflammatory papuleswith acquired reactive perforating collagenosis. Dermatology 2008; 216: 239–42PubMedCrossRef
71.
Bakos L, Bakos RM. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol 2007; 143: 1223–4PubMed
72.
Li JC, Xu AE. Facial acne during topical pimecrolimus therapy for vitiligo. Clin Exp Dermatol 2009; 34: e489–90CrossRef
73.
74.
Cohen LK, George W, Smith R. Isoniazid-induced acne and pellagra: occurrence in slow inactivators of isoniazid. Arch Dermatol 1974; 109: 377–81PubMedCrossRef
75.
76.
Holdiness MR. Adverse cutaneous reactions to antituberculosis drugs. Int J Dermatol 1985; 24: 280–5PubMed
77.
Hesse PG. Antitubercular therapy and acneiform exanthema [in German]. Dermatol Wochenschr 1966; 152: 305–12PubMed
78.
Nwokolo U. Acneiform lesions in combined rifampicin treatment in Africans [letter]. Br Med J 1974; 3: 473PubMedCrossRef
79.
Levantine A, Almeyda J. Cutaneous reactions to antituberculosis drugs. Br J Dermatol 1972; 86: 651–5PubMedCrossRef
80.
81.
Rosenberg FR, Einbinder J, Walzer RA, et al. Vegetating iododerma: an immunologic mechanism. Arch Dermatol 1972; 105: 900–5PubMedCrossRef
82.
83.
Kint A, Van Herpe L. Iododerma. Dermatologica 1977; 155: 171–3PubMed
84.
Heydenreich G, Larsen PO. Iododerma after high dose urography in an oliguric patient. Br J Dermatol 1977; 97: 567–9PubMedCrossRef
85.
Belaïch S, Crickx B, Schwartz C, et al. Vegetating iododerma following lymphography. Ann Dermatol Venereol 1985; 112: 699–700PubMed
86.
Wilkin JK, Strobel D. Iododerma occurring during thyroid protection treatment. Cutis 1985; 36: 335–7PubMed
87.
Boudoulas O, Siegle RJ, Grimwood RE. Iododerma occurring after orally administered iopanoic acid. Arch Dermatol 1987; 123: 387–8PubMedCrossRef
88.
Soria C, Allegue F, España A, et al. Vegetating iododerma with underlying systemic diseases: report of three cases. J Am Acad Dermatol 1990; 22: 418–22PubMedCrossRef
89.
Vaillant L, Pengloan J, Blanchier D, et al. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. Clin Exp Dermatol 1990; 15: 232–3PubMedCrossRef
90.
Noonan MP, Williams CM, Elgart ML. Fungating pustular plaques in a patient with Graves’ disease: iododerma. Arch Dermatol 1994; 130: 786–7, 789-90PubMedCrossRef
91.
Alpay K, Kurkcuoglu N. Iododerma: an unusual side effect of iodide ingestion. Pediatr Dermatol 1996; 13: 51–3PubMedCrossRef
92.
Ricci C, Krasovec M, Frenk E. Amiodarone induced iododerma treated by cyclosporine. Ann Dermatol Venereol 1997; 124: 260–3PubMed
93.
Miranda-Romero A, Sánchez-Sambucety P, Esquivias Gómez JI, et al. Vegetating iododerma with fatal outcome. Dermatology 1999; 198: 295–7PubMedCrossRef
94.
Pranteda G, Grimaldi M, Salzetta M, et al. Vegetating iododerma and pulmonary eosinophilic infiltration: a simple co-occurrence? Acta Derm Venereol 2004; 84: 480–1PubMed
95.
Paul AK, Al-Nahhas A, Ansari SM, et al. Skin eruptions following treatment with iodine-131 for hyperthyroidism: a rare and un-reported early/ intermediate side effect. Nucl Med Rev Cent East Eur 2005; 8: 125–7PubMed
96.
Aydingöz IE, Göktay F, Serdar ZA, et al. Iododerma following sitz bath with povidone-iodine. Australas J Dermatol 2007; 48: 102–4PubMedCrossRef
97.
Massé M, Falanga V, Zhou LH. Use of topical povidone-iodine resulting in an iododerma-like eruption. J Dermatol 2008; 35: 744–7PubMedCrossRef
98.
Arditti J, Follana J, Bonerandi JJ, et al. Bromide vegetating skin diseases after treatment by a bromocalcic specialty. Eur J Toxicol Environ Hyg 1976; 9: 59–63PubMed
99.
100.
Roman P, Bourgeois-Droin C. Bromide-induced skin diseases. Ann Dermatol Venereol 1999; 126: 831–4PubMed
101.
Maffeis L, Musolino MC, Cambiaghi S. Single-plaque vegetating bromoderma. J Am Acad Dermatol 2008; 58: 682–4PubMedCrossRef
102.
Herxheimer K. Uber chlorakne [letter]. Münchener Medicinische Wochenschrift 1899; 46: 278
103.
104.
105.
Rodríguez-Pichardo A, Camacho F. Chloracne as a consequence of a family accident with chlorinated dioxins [letter]. J Am Acad Dermatol 1990; 22: 1121PubMedCrossRef
106.
Soper LE, Vitez TS, Weinberg D. Metabolism of halogenated anaesthetic agents as a possible cause of acneiform eruptions. Anaesth Analg 1973; 52: 125–7CrossRef
107.
108.
109.
Joynt RL. Dantrolene sodium: long term effects in patients with muscle spasticity. Arch Phys Med Rehabil 1976; 57: 212–7PubMed
110.
Pembrocke AC, Sexena SR, Katiara M, et al. Acne induced by dantrolene. Br J Dermatol 1981; 104: 465–8CrossRef
111.
Mowbray M, Sinclair SA, Allan SJ. Severe acneiform eruption exacerbated by dantrolene sodium. Clin Exp Dermatol 2009; 34: 248–9PubMedCrossRef
112.
113.
Scott C, Staughton RC, Bunker CJ, et al. Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy. Int J STD AIDS 2008; 19: 493–5PubMedCrossRef
114.
Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235–46CrossRef
115.
Busam KJ, Capoiece P, Motzer R, et al. Cutaneous side effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C 225. Br J Dermatol 2001; 144: 1169–76PubMedCrossRef
116.
Walon L, Gilbeau C, Lachapelle JM. Acneiform eruptions induced by cetuximab. Ann Dermatol Venereol 2003; 130: 443–6PubMed
117.
Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238–41PubMedCrossRef
118.
Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 2005; 41: 107–27PubMedCrossRef
119.
Hannoud S, Rixe O, Bloch J, et al. Skin signs associated with epidermal growth factor inhibitors. Ann Dermatol Venereol 2006; 133: 239–42PubMedCrossRef
120.
Segaert S, Van Custem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–33PubMedCrossRef
121.
Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on longterm treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009; 161: 515–21PubMedCrossRef
122.
123.
Scope A, Agero AL, Dusza AL, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390–6PubMedCrossRef
124.
Deplanque G. CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients [abstract no. 9019]. ASCO Annual Meeting; 2010 Jun 4-8; Chicago (IL)
125.
126.
Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–12PubMedCrossRef
127.
Martín JM, Jordá E, Monteagudo C, et al. Follicular acneiform eruption induced by imatinib. J Eur Acad Dermatol Venereol 2006; 20: 1368–70PubMedCrossRef
128.
Fleta-Asín B, Vañó-Galván S, Ledo-Rodríguez A, et al. Facial acneiform rash associated with sorafenib [letter]. Dermatol Online J 2009; 15: 7PubMed
129.
Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007; 7: 127–34PubMedCrossRef
130.
Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007; 32: 71–4PubMed
131.
Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045–51PubMedCrossRef
132.
Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16: 4452–60PubMedCrossRef
133.
Michot C, Guillot B, Dereure O. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology 2010; 220: 49–50PubMedCrossRef
134.
Keenan BP, Abuav R. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme [letter]. Arch Dermatol 2010; 146: 577PubMedCrossRef
135.
Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16: 1613–23PubMedCrossRef
136.
Bassi E, Poli F, Charachon A, et al. Infliximab-induced acne: report of two cases. Br J Dermatol 2007; 156: 402–3PubMedCrossRef
137.
Sladden MJ, Clarke PJ, Mitchell B. Infliximab-induced acne: report of a third case [letter]. Br J Dermatol 2008; 158: 172PubMedCrossRef
138.
Sun G, Wasko CA, Hsu S. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J Drugs Dermatol 2008; 7: 69–71PubMed
139.
Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010; 11: 459–64PubMedCrossRef
140.
Pour L, Hajek R, Zdenek A, et al. Skin lesions induced by bortezomib. Haematologica 2005; 90 (12 Suppl.): ECR44
Metadaten
Titel
Drug-Induced Acneiform Eruption
verfasst von
Aurélie Du-Thanh
Nicolas Kluger
Houdna Bensalleh
Prof. Bernard Guillot
Publikationsdatum
01.08.2011
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2011
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/11588900-000000000-00000

Weitere Artikel der Ausgabe 4/2011

American Journal of Clinical Dermatology 4/2011 Zur Ausgabe

Review Article

Longitudinal Erythronychia

Review Article

Pediatric Psychocutaneous Disorders

Review Article

Diagnosis and Treatment of Cutaneous Mastocytosis in Children

Case Letter

Pemphigus Vulgaris with Plaque-Type Psoriasis Successfully Treated with Cyclosporine Monotherapy

Short Communication

Clinical and Laboratory Features in Acute Generalized Pustular Psoriasis

Original Research Article

Childhood Vitiligo in China

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise